ITW:NYSEIllinois Tool Works Inc. Analysis
Data as of 2026-05-24 - not real-time
$252.20
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Illinois Tool Works posted Q1 2026 revenue of $4.02 billion, up 4.6% YoY, beating consensus. GAAP EPS came in at $2.66, a 3.5% beat, and operating margin improved to 25.4%, adding 60 bps. Management highlighted strong demand in automotive and construction segments and announced a 2.55% dividend. Despite the beat, the stock slipped roughly 3% on the day, reflecting profit‑taking and lingering concerns over leverage. The company’s free cash flow of $2.22 billion supports the dividend payout of $6.44 per share, yielding 2.55%. However, total debt of $9.15 billion versus cash of $0.83 billion leaves a debt‑to‑equity ratio above 280%.
On the technical side, ITW trades at $252.20, below its 20‑day SMA of 254.8 and 50‑day SMA of 261.2, with a neutral RSI of 43.7. The MACD histogram turned positive, indicating a mild bullish tilt, but volume is on a downtrend. Valuation metrics are mixed: a trailing PE of 23.4 is below the industry average of 29.7, yet a discounted‑cash‑flow model pins fair value near $93, implying significant overvaluation. The extreme‑greed sentiment index (91.6) suggests market enthusiasm may be overstated. High ROE (96.8%) is driven largely by leverage, and the beta of 0.63 points to lower market volatility. Overall, the stock offers a solid dividend and resilient margins but faces valuation pressure and debt risk.
On the technical side, ITW trades at $252.20, below its 20‑day SMA of 254.8 and 50‑day SMA of 261.2, with a neutral RSI of 43.7. The MACD histogram turned positive, indicating a mild bullish tilt, but volume is on a downtrend. Valuation metrics are mixed: a trailing PE of 23.4 is below the industry average of 29.7, yet a discounted‑cash‑flow model pins fair value near $93, implying significant overvaluation. The extreme‑greed sentiment index (91.6) suggests market enthusiasm may be overstated. High ROE (96.8%) is driven largely by leverage, and the beta of 0.63 points to lower market volatility. Overall, the stock offers a solid dividend and resilient margins but faces valuation pressure and debt risk.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Q1 earnings beat but price fell 3% post‑release
- High debt‑to‑equity ratio (≈280%) raises balance‑sheet risk
- Technical price below short‑term moving averages
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Strong free cash flow sustains dividend payout
- Operating margins expanding modestly
- Valuation remains above DCF fair value
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Sustainable dividend yield of 2.55%
- Diversified global exposure across industrial segments
- Potential valuation correction due to leverage
Key Metrics & Analysis
Financial Health
Revenue Growth4.60%
Profit Margin19.32%
P/E Ratio23.4
ROE96.85%
ROA17.04%
Debt/Equity283.22
P/B Ratio22.5
Op. Cash Flow$3.2B
Free Cash Flow$2.2B
Industry P/E29.7
Technical Analysis
TrendNeutral
RSI43.7
Support$244.37
Resistance$273.25
MA 20$254.81
MA 50$261.23
MA 200$260.84
MACDBullish
VolumeDecreasing
Fear & Greed Index91.61
Valuation
Fair Value$93.18
Target Price$274.54
Upside/Downside8.86%
GradeOvervalued
TypeBlend
Dividend Yield2.55%
Risk Assessment
Beta0.63
Volatility22.14%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.